SEC Form 4 · accession 0000921895-18-002522
PLx Pharma Inc. · PLXP
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Efthymios Deliargyris
Officer — Chief Medical Officer
Period of report
Aug 29, 2018
Accepted (ET)
Aug 31, 2018 · 4:23 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001497504
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock option (right to buy)F1 | $3.18 | Aug 29, 2018 | A | 70,000 | A | — | Aug 29, 2028 | Common Stock | 70,000 | 70,000 | D |
Explanation of responses
- F1The stock options vest as follows: 23,333 options vest on August 29, 2019, 23,333 vest on August 29, 2020 and 23,334 options vest on August 29, 2021.